This is a Validated Antibody Database (VAD) review about human TNFRSF10C, based on 4 published articles (read how Labome selects the articles), using TNFRSF10C antibody in all methods. It is aimed to help Labome visitors find the most suited TNFRSF10C antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
TNFRSF10C synonym: CD263; DCR1; DCR1-TNFR; LIT; TRAIL-R3; TRAILR3; TRID; tumor necrosis factor receptor superfamily member 10C; TNF-related apoptosis-inducing ligand receptor 3; antagonist decoy receptor for TRAIL/Apo-2L; cytotoxic TRAIL receptor-3; decoy TRAIL receptor without death domain; decoy receptor 1; lymphocyte inhibitor of TRAIL; tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain

R&D Systems
mouse monoclonal (90906)
  • flow cytometry; human; fig st1
In order to find cell-surface markers specific to human neutrophils, R&D Systems TNFRSF10C antibody (R&D Systems, FAB6302P) was used in flow cytometry on human samples (fig st1). Exp Cell Res (2016) ncbi
mouse monoclonal (90906)
  • flow cytometry; human; 5 ug/ml
R&D Systems TNFRSF10C antibody (R&D Systems, 90906) was used in flow cytometry on human samples at 5 ug/ml. J Biol Chem (2011) ncbi
Enzo Life Sciences
mouse monoclonal (HS301)
  • flow cytometry; human
Enzo Life Sciences TNFRSF10C antibody (Alexis, HS301) was used in flow cytometry on human samples . Br J Cancer (2013) ncbi
goat polyclonal
  • immunohistochemistry; human; 1:50
Enzo Life Sciences TNFRSF10C antibody (Alexis Biochemicals, ALX-210-744-C200) was used in immunohistochemistry on human samples at 1:50. Head Neck (2011) ncbi
Articles Reviewed
  1. Lakschevitz F, Hassanpour S, Rubin A, Fine N, Sun C, Glogauer M. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res. 2016;342:200-9 pubmed publisher
  2. Meijer A, Kruyt F, van der Zee A, Hollema H, Le P, Ten Hoor K, et al. Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL. Br J Cancer. 2013;109:2685-95 pubmed publisher
  3. Moriwaki K, Shinzaki S, Miyoshi E. GDP-mannose-4,6-dehydratase (GMDS) deficiency renders colon cancer cells resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor- and CD95-mediated apoptosis by inhibiting complex II formation. J Biol Chem. 2011;286:43123-33 pubmed publisher
  4. Yoldas B, Ozer C, Ozen O, Canpolat T, Dogan I, Griffith T, et al. Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer. Head Neck. 2011;33:1278-84 pubmed publisher